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THE introduction of 1:3:7:9-tetramethyluric acid as a solubilizer for
3:4-benzpyrene (Weil-Malherbe, 1946) has made it possible to prepare aqueous
solutions of benzpyrene suitable for injection. If solubilizer solutions of equal
concentration (weight/volume) are compared, a tetramethyluric acid solution
will dissolve about five times more benzpyrene than a caffeine solution and
about 10 times more than a deoxycholate solution.
It has been suggested that the solubilization of hydrocarbons by purines is
connected with the formation of coordination complexes (Weil-Malherbe, 1946).
A similar mechanism was assumed to underlie the activation of elimination and
carcinogenicity observed when benzpyrene is injected in solvents containing
cholesterol or cholestanol (Weil-Malherbe, 1947). It was therefore of interest
to study the rate of elimination and the carcinogenic activity of solubilized
benzpyrene. It was anticipated that in the absence of a stable lipoid depot the
dispersion of benzpyrene and its absorption by the surrounding tissues would
be greatly speeded up. The additional effect of the solubilizer can only be
gauged if allowance is made for the different- physical conditions resulting from
the absence of a lipoid depot. The rate of elimination after the injection of
colloidal aqueous or ethereal solutions of benzpyrene was therefore also
measured. Peacock and Beck (1938) obtained only a few tumours with 0 5-1
mg. benzpyrene subcutaneously administered to mice either as the powdered
solid or in ethyl ether solution, and they attributed this to a more rapiddispersal
and elimination of the hydrocarbon. The effects of aqueous solutions of benz-
pyrene made up with the aid of a solubilizer do not appear to have been ade-
quately studied. Gummel and Rarei (1939) used sodium cholestenone sul-
phonate solutions as a solvent for benzpyrene, but their method of preparation
(solution of benzpyrene in acetone, addition to cholestenone sulphonate solution
and evaporation of acetone) suggests that benzpyrene may have been present
partly in colloidal solution. They found after five months, as a result of daily
injections in rabbits, chronic degenerative changes in parenchymatous tissues,
such as amyloidosis of spleen and liver, necrosis of liver cells and testicuilar
atrophy.
EXPERIMENTAL.
1:3:7:9-Tetramethyluric acid was prepared according to Biltz and Strufe
(1916).
Tetramethyluric acid solutions of benzpyrene were prepared by shaking the
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purine solution with an excess of solid hydrocarbon for 3-4 hours at room
temperature. If the concentration of tetramethyluric acid was higher than
3 per cent the mixtures were warmed on a water bath to about 500 C. and kept
there for half an hour with constant stirring. Before use the solutions were
filtered through Whatman No. 5 filter paper. Solutions containing 4 or 5 per
cent tetramethyluric acid were kept at body temperature to prevent crystalli-
zation.
Deoxycholate solutions of benzpyrene were prepared in a similar way.
A colloidal solution ofbenzpyrene was prepared by the method ofFeigenbaum
(1944). It was filtered before use.
Benzpyrene was estimated fluorimetrically (Weil-Malherbe, 1944).
Glaxo FF mice of both sexes were used for the experiments.
Elimination Rates.
It was considered desirable to introduce as little variation of technique as
possible. The same volume of solution as that used in the experiments with
lipoid solvents, 0*3 ml., was therefore adhered to for the injections. A 5 per
cent solution of tetramethyluric acid which, at body temperature, is practically
saturated will dissolve about 0-2 mg. of benzpyrene in 0 3 ml., while 0 3 ml. of
a 4 per cent solution contain about 0 15 mg. of benzpyrene. The 5 per cent
solution, ifinjected in amounts of0 3 ml., is appreciably toxic, causing a mortality
of about 30 per cent, whereas the mortality is only about 7 per cent with the
4 per cent solution. The latter was therefore chosen for the elimination
experiments.
A solution of sodium deoxycholate of the same concentration (4 per cent)
only dissolves about 15 ,±g. benzpyrene per 0 3 ml. and, moreover, causes skin
damage (haemorrhagic oedema followed by necrosis) in a number of cases. The
subcutaneous injection of 0 3 ml. ether solution also proved rather toxic, and led
to deep anaesthesia of all and the subsequent death of 21 outt of 35 mice.
In all four series cases of skin necrosis were observed which developed near
the site of injection after 2-4 weeks. The necrotic patch of skin usually showed
a brilliant bluish-white fluorescence in ultraviolet light. A scab usually de-
veloped which was finally sloughed off. The fluorescent substance was lost in
the process, and analyses showed that there was practically no benzpyrene left
in such mice. Because of the prevalence of this phenomenon, especially in the
ether series, the analyses had to be confined to the first 4-5 weeks. In the
tetramethyluric acid series the majority of estimations performed after the
eighth day showed that the benzpyrene content had fallen below the level of
sensitivity of the method. To avoid an undesirable bias the estimations which
gave a measurable result after this date were omitted from the statistical analysis,
but they are shown in Fig. 1. In Fig. 1-4 the values of log S (-,g. benzpyrene
found) were plotted against the time t (days after injection). The straight line
represents the linear regression of log S on t, calculated by the method of least
squares. The regression coefficients and their standard errors are given in
Table I.
It is obvious that the rate of elimination in the two experiments in which
solubilizers were used is of quite a different order from that observed in the
other two experiments. The differences within these two groups are not
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FIG. 1.-Elimination rate of 3:4-benzpyrene after subcutaneous injection of a saturated
solution in 4 per cent aqueous tetramethyluric acid solution. Only the values to the left
of the broken line were used for the calculation of the linear regression. Bracketed points
represent analyses in which no measurable amounts of benzpyrene could be detected.
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FIG. 2.-Elimination rate of 3:4-benzpyrene after subcutaneous injection of a saturated
solution in 4 per cent aqueous sodium deoxycholate solution.
statistically significant (P > 0 05). With ethereal or colloidal solutions the
elimination proceeds at practically the same rate as was observed with various
lipoid solvents, at least within the first 4-5 weeks. After this time ulceration
may intervene and cause a sudden and almost complete loss of benzpyrene.H. WEIL-MALHERBE
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FIG. 4.-Elimination rate of 3:4-benzpyrene after subcutaneous injection of a solution in
ethyl ether.
TABLE I.-Elimination of 3: 4-Benzpyren6 Dissolved in Non-lipoid
Vehicles After Subcutaneous Injection.
Solution.
4% tetramethyluric acid .
4% sodium deoxycholate.
Colloidal
Ethyl ether
Initial
amount of
benzpyrene.
(,ug. in 03 ml.)
160
14-3
100
307
Number of
observa-
tions.
25
16
20
13
Linear
regression
coefficient.
- 0-214
- 0-127
- 0 0388
- 0-0264
Standard
error.
0-0532
0-0234
0-00677
0-00854
This may account for the impression expressed by Peacock and Beck (1938)
that absorption and elimination was faster after injection of ether solutions of
benzpyrene than it was after injection of lipoid solutions. On the other hand,
there is a remarkable increase ofthe elimination rate in the presence ofsolubilizers,
I I
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amounting to an acceleration of about 5-10 times. In Fig. 5 the elimination
rates of benzpyrene found in a number ofexperiments with lipoid and non-lipoid
solvents are compared. The elimination constant of - 0-214 for tetramethyluric
acid-solution corresponds to a half-lifetime of 1 4 days, whereas the constant for
tricaprylin, - 0-0157; corresponds to a half-lifetime of 19 1 days.
There is a rather wide scatter which becomes more marked as the elimination
rate increases. In the tetramethyluric-acid series an initial divergence from
linearity has to be assumed, indicating a rapid drop in the first few hours after
injection to a level from which the further elimination proceeds in a linear fashion.
Fairly high values of benzpyrene persist in a few sporadic cases even after the
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FIG. 5.-Elimination rates of 3:4-benzpyrene dissolved in different solvents after sub-
cutaneous injection:
(1) From this paper.
(2) From Weil-Malherbe (1947).
(3) From Weil-Malherbe & Dickens (1946).
eighth day. These were cases showing necrotic skin areas impregnated with
fluorescent material. Any benzpyrene trapped in the necrotic tissues pre-
sumably remains fixed there. If this interpretation is correct, the analyses of
such cases are immaterial to the evaluation of the elimination constant and
may be neglected.
Metabolism of Benzpyrene after Injection in Tetramethyluric Acid Solution.
In view of the increased elimination rate of benzpyrene after its injection in
tetramethyluric acid solution the question arose whether a change in its meta-
bolism took place. In particular the possibility of a urinary excretion of a
complex between tetramethyluric acid and either unchanged or oxidized benz-
pyrene had to be considered. Twenty rats were therefore injected daily with
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1 ml. of a 4 per cent solution of tetramethyluric acid saturated with benzpyrene
for 12 days. An estimated total of 100 mg. benzpyrene was thus administered.
The rats were kept in two metabolism cages, and their urine was collected in
brown bottles containing 20 ml. 10 N sulphuric acid. The combined urine was
filtered and extracted ten times with ether in a separating funnel. The pooled
ether extracts were washed with water, dried and evaporated. After extraction
the urine was neutralized with baryta, filtered and concentrated in vacuo to
300 ml. It was then extracted with chloroform in a separating funnel.
The residue from the ether extract was taken up in benzene, and the benzene
solution extracted with a small volume of N sodium hydroxide solution. The
soda extract was saturated with solid ammonium sulphate and re-extracted
with benzene (phenolic fraction). Both benzene solutions, the phenolic and the
neutral fraction, were dried and passed through columns of silica gel. The
filtrates were then passed through columns of alumina and developed with
benzene. No trace of unchanged benzpyrene or of benzpyrene quinones was
detected in the neutral fraction. The phenolic fraction, after filtration through
silica gel, showed a bluish-white fluorescence; on the alumina column a band
with yellow fluorescence formed and moved slowly down. This was taken as an
indication ofthe presence of a phenolic metabolite, but the substance was present
in traces onlv and could not be further characterized.
The benzene insoluble residue of the ether extract slowly crystallized. On
further investigation, which need not be described in detail, it appeared mainly
to consist of a mixture of methylmalonic (Boyland and Levi, 1936) and succinic
acids.
Several crystalline fractions were also isolated from the chloroform extracts.
Most of them were nitrogen-free and were not identified. Small quantities of
two nitrogen-containing substances (m.p. 157 and 2060 C.) were not identical
with tetramethyluric acid.
The result of the metabolism experiment is in agreement with the prevailing
views on the fate ofinjected benzpyrene, the bulk ofwhich is apparently excreted
with the faeces in the form of a phenolic derivative, and no unchanged benz-
pyrene and only traces of the phenolic metabolite pass into the urine (Berenblum
and Schoental, 1943). The situation, at least as far as urinary excretion is
concerned, does not seem to be modified by the presence of tetramethyluric acid.
It is likely, therefore, that the increase of the elimination rate is largely a local
effect, perhaps due to a more rapid penetration across the cell membranes. It
is interesting to note that no unchanged tetramethyluric acid was found in the
urine either. As is well known, methyluric acids may undergo partial or com-
plete demethylation at one or several positions of the molecule within the body
(Myers and Hanzal, 1946).
Carcinogenic Activity of 3:4-Benzpyrene Dissolved in Aqueous
Tetramethyluric Acid Solution.
A series of mice were given a single injection of 0 3 ml. of a 5 per cent solution
of tetramethvluric acid in water, saturated with benzpyrene. The amount of
benzpyrene injected in this way was about 0-2 mg. per mouse. Among 21 mice
alive after 8 months only one sarcoma arose locally, and this appeared 5 months
after the injection.
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In a second experiment a series of 20 mice were injected subcutaneously
with 0*3 ml. of a 1 per cent aqueous solution of tetramethyluric acid saturated
with benzpyrene, while an equal amount of a 1 per cent tetramethyluric acid
solution free from benzpyrene was injected into another series of 20 mice. The
injections were repeated twice weekly for 32 weeks. As a single dose contained
about 10 ,ug. benzpyrene, each mouse received altogether about 0-32 mg. The
experiment, which is now in its seventh month, has produced one local tumour
so far.
DISCUSSION.
The results show two points of interest: (1) When benzpyrene is injected in
colloidal or ethereal solution, its elimination proceeds at a rate not much different
from that observed with several oilv solutions (Fig. 5). The dispersal and
absorption of benzpyrene do not therefore seem to be greatly facilitated by
this form of application or, if they are, do not thereby appreciably accelerate
the rate of elimination. Little is known about the carcinogenic response to
these solutions. Morton and Mider (1939) observed in C 57 black mice an
incidence of 50 per cent tumours after the subcutaneous injection of 0-25 mg.
benzpyrene in colloidal solution, as compared with an incidence of 78 per cent
after the injection of a sesame oil solution. It may be recalled that sesame
oil has a procarcinogenic effect (Dickens and Weil-Malherbe, 1946); the incidence
observed with the colloidal solution is close to the tricaprylin norm. Peacock
and Beck (1938) found no tumours six months after the subcutaneous injection
of mice with 0 5 mg. benzpyrene in 01 ml. ether. This is a surprising result.
In the writer's experiments the injection of ethereal solutions led to frequent
skin necrosis and demarcation, but no mention of it is made by Peacock and
Beck. A reinvestigation with a careful watch for leakage or ulceration seems
desirable.
(2) The elimination of benzpyrene is considerably faster when it is injected
in an aqueous solution of a solubilizer than in a colloidal or ethereal solution.
This result is unexpected for the following reasons: (1) The solubilization of
benzpyrene increases with the square of the concentration of tetramethyluric
acid (Weil-Malherbe, 1946) or sodium deoxycholate (Weil-Malherbe, unpub-
lished) in the concentration range used. Precipitation is therefore caused by
dilution, such as takes place when the injected solution mixes with the tissue
fluids. (2) Addition ofelectrolytes also leads to precipitation. (3) The complexes
between solubilizer molecules and benzpyrene molecules are assumed to be
largely dissociated in solution (Weil-Malherbe, 1946), and a more rapid diffusion
of the water-soluble solubilizer molecule in the tissues might be expected, a
process which would also lead to precipitation of benzpyrene.
One would anticipate, therefore, that benzpyrene would be deposited and
subsequently taken up in combination with, or solution by, tissue components
in a similar manner, whether dissolved in ether, in colloidal solution or in an
aqueous solution of a solubilizer. The difference in the rate of elimination,
however, leads to the conclusion that this is not the case, and that theinteraction
between solubilizer and hydrocarbon persists to some extent after injection,
presumably long enough in some way to assist the transport of the hydrocarbon
across the cell membranes.
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In the case ofcholesterol and cholestanol a correlation has also been postulated
between the increased rate of elimination of benzpyrene and the formation of
association complexes (Weil-Malherbe, 1947). But, whereas here the speedier
elimination was associated with a higher tumour incidence, the tumour incidence
is negligible with tetramethyluric acid solutions of benzpyrene. A number of
possible explanations offer themselves: (1) There may be a rate of metabolism
of benzpyrene which is optimal for carcinogenesis, and this optimum may be
exceeded in the case of tetramethyluric acid solutions. If this is so, not only
the intensity, but also the duration of the process would be of importance. It
need not beimplied in this assumption that the metabolic reactions are a necessary
cause of the carcinogenic stimulus; they may merely be a corollary to a simul-
taneous but unrelated activation of the reactions which initiate the carcinogenic
metamorphosis. (2) The total quantities of benzpyrene injected or the effective
concentrations in the tissue may have been insufficient. The dose used in the
single-injection experiment was not a great deal below that which is found to be
effective when applied in an oily vehicle. But a large proportion of it was
eliminated (luring the first few hours after the injection. This sudden drop in
benzpyrene content suggests that part of the injected fluid may have escaped
into the circulation, and was therefore metabolized and eliminated at a much
faster rate than the benzpyrene which remained in the subcutaneous tissues.
In the mice which were given repeated injections of small doses of benzpyrene
the chances of a sufficient local concentration being reached at the site ofinjection
were of course smaller still. This was intentional, as it was the object of the
experiment to induce not so much local as remote changes. However, the
experiment will be repeated with higher doses.
Shear (1941) obtained only one local sarcoma out of 24 mice of Strains A
and D, 16 months after injection of 0 5 ml. of a 0-25 per cent. aqueous solution
of the sodium salt of the molecular compound formed by the combination of one
molecule of 1:2:5:6-dibenzanthracene with four molecules of deoxycholic
acid. A number of multiple lung tumours were observed in Strain A mice.
The dose injected, 0*17-0-18 mg. dibenzanthracene, is effective if administered
in an oily solvent. In similar experiments with an aqueous solution of the
sodium salt of the 20-methylcholanthrene-deoxycholic acid compound, in which
0 5 ml. of a 0-25 per cent solution were injected (about 0-18 mg. methylcholan-
threne per injection), two tumours arose amongst six Strain A mice and none in
six Strain D mice after three months (Shear, 1936). At that time, and again
after four months, the mice were reinjected with the same amount. After six
months all Strain A mice and three Strain D mice had developed local tumours.
This suggests that, provided the quantity is high enough in relation to the
activity, the solubilization of carcinogenic hydrocarbons does not preclude their
activity. (3) The solubilization of benzpyrene may bring about a qualitative
change of its metabolism. Although the analysis of the urine of rats which had
been injected with a benzpyrene-tet.ramethyluric acid solution gave no indication
of a urinary excretion of unchanged benzpyrene or of substantial amounts of a
metabolite, the rapid initial drop of benzpyrene content after injection is a
digression from the usual course of events, whether the change concerns only
the site or also the mechanism of the metabolic transformations.
It is at present impossible to decide which of these explanations is correct.
But the three possibilities are by no means exclusive to each other and may all
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apply together in varying degrees, with the second factor probably predomi-
nating.
SUMMARY.
Mice were subcutaneously injected with the following solutions of 3:4-
benzpyrene: aqueous solutions made up with the aid of 1:3:7:9:tetramethyl-
uric acid or sodium deoxycholate as solubilizers, an aqueous colloidal solution,
and a solution in ethyl ether, and the rate of elimination of benzpyrene was
measured. It was found that with the ethereal and colloidal solutions the rate
of elimination was of the same order of magnitude as that observed with several
lipoid solvents, while it was 5-10 times4higher in the experiments in which
solubilizers were used. The increase in the elimination rate brought about by
tetramethyluric acid is not accompanied by a urinary excretion of unchanged
benzpyrene or of substantial amounts of a metabolite, as shown by experiments
on rats. No unchanged tetramethyluric acid was detected in the urine either.
Out of 21 mice injected with a single dose of a solution of tetramethyluric
acid containing about 0*2 mg. benzpyrene per dose, only one developed a sarcoma
after 5 months. One tumour arose in a series of 20 mice injected twice weekly
for 32 weeks with a solution oftetramethyluric acid containing 10 ,ug. benzpyrene
per.injection.
The results have been discussed.
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